2{alpha},3{alpha}-Epithio-5{alpha}-androstan-17{beta}-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer --A Preliminary Clinical Trial--期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

2{alpha},3{alpha}-Epithio-5{alpha}-androstan-17{beta}-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer --A Preliminary Clinical Trial--

Authors:	KUMAOKA, SOICHI TAKATANI, OSAMU YOSHIDA, MINORU MIURA, SHIGETO TAKAO, TETSUTO HAMANAKA, YUJI IZUO, MASARU OKADA, TADAKAZU

Affiliation:	¹ National Cancer Center Research Institute Tsukiji, Chuo-ku, Tokyo. ² National Cancer Center Hospital ³ Aichi Cancer Center Hospital ⁴ First Department of Surgery, Osaka University Medical School ⁵ Department of Surgery, Gunma University, School of Medicine

Abstract:	A new orally active anti-estrogenic steroid, 2 ${alpha}$ ,3 ${alpha}$ -epithio-5 ${alpha}$ -androstan-17ß-yl1-methoxycyclopentyl ether (10364-S) was given to 41 advancedbreast cancer patients. Most patients were given a daily doseof 20 mg. The study was preliminary and not a controlled trialusing an already proven androgenic steroid. The remission rateon giving this compound to advanced breast cancer was 11/41or 26.8% and the average duration of the remission was 10.5months. Hoarseness (8/41, 19.5%) and hirsutism (5/41, 12.2%) were relativelyoften seen as virilizing side effects. No unfavorable effectson the hematopoietic organs, the liver or on calcium metabolismwere recognized in the study.

Keywords:
本文献已被 Oxford 等数据库收录！